Abstract
Peritumoral edema is a critical factor in the infiltration and recurrence of glioma. While Photodynamic Therapy (PDT) is an effective treatment for killing cancer cells, it often exacerbates peritumoral edema, potentially reducing its overall therapeutic benefit. This study investigated whether combining PDT with the diuretic torasemide could mitigate this side effect by modulating the expression of matrix metalloproteinase 2 (MMP2) and sodium-potassium-chloride cotransporter 1 (NKCC1). Using a rat C6 glioma model, researchers found that PDT alone suppressed tumor growth by reducing MMP2 but increased edema by upregulating NKCC1. The addition of torasemide successfully downregulated NKCC1 expression and reduced edema without affecting the anti-tumor suppression of MMP2, leading to significantly prolonged survival times.
Introduction
Gliomas are highly aggressive brain tumors characterized by invasive growth patterns that make complete surgical resection nearly impossible. Photodynamic Therapy (PDT) has emerged as a promising adjuvant treatment. By utilizing photosensitizing agents and specific wavelengths of light, PDT generates reactive oxygen species (ROS) that induce localized tumor cell death.
However, PDT presents a significant clinical challenge: it increases the permeability of the blood-tumor barrier, leading to peritumoral edema. This accumulation of fluid around the tumor site can cause severe neurological complications and may even facilitate further cancer cell migration. This study explores the use of torasemide, a loop diuretic, to counteract PDT-induced edema by targeting the molecular pathways responsible for fluid transport in the brain.
Methods and Materials
The study utilized adult male Wistar rats inoculated with rat glioma C6 cells. Seven days after inoculation, the presence of the tumor was confirmed using Magnetic Resonance Imaging (MRI).
The rats were randomly assigned to four experimental groups (n=15 each): a control group, a PDT-only group (80 J/cm²), a torasemide-only group (5 mg/kg), and a combination PDT + torasemide group. Researchers evaluated peritumoral edema using the wet-to-dry (W/D) weight ratio of harvested brain tissue. Molecular analysis included RT-qPCR, Western blotting, and immunohistochemistry to measure the expression of MMP2 (a marker for tumor invasion) and NKCC1 (a co-transporter protein central to edema formation).
Key Results
The study revealed a complex interplay between the treatment modalities and protein expression levels.
Molecular Modulation
PDT was found to significantly reduce the expression of MMP2 compared to the control group, which correlates with its ability to inhibit tumor growth and invasion. However, PDT also significantly increased the expression of NKCC1, explaining the observed increase in peritumoral edema. The introduction of torasemide in the combination group specifically addressed this issue. While it did not interfere with the beneficial suppression of MMP2, it significantly downregulated the expression of NKCC1 compared to the PDT-only group.
Edema and Survival
The quantitative measure of edema (W/D ratio) reflected these molecular changes. The PDT-only group showed the highest W/D ratio (5.12), indicating significant swelling. In contrast, the PDT + Torasemide group maintained a W/D ratio (4.79) close to the control levels (4.76).
Most importantly, the combination therapy dramatically improved survival outcomes. While the control group survived an average of 24.5 days and the PDT-only group survived 30.6 days, the rats receiving both PDT and torasemide survived for an average of 47.7 days—nearly doubling the survival time of the control group.
Discussion and Conclusion
The findings suggest that the edema following PDT is driven by the upregulation of NKCC1, possibly triggered by treatment-induced ischemia or hypoxia. By inhibiting NKCC1, torasemide effectively manages the fluid buildup without compromising the anti-tumor efficacy of the PDT. This study provides a strong molecular rationale for a combinatorial approach in glioma treatment, maximizing the therapeutic window of photodynamic therapy by simultaneously targeting tumor growth and treatment-induced side effects.
Summary updated